Anebulo Pharmaceuticals is a clinical-stage pharmaceutical company developing treatments for cannabis-induced toxicity. Its lead product candidate, selonabant (formerly ANEB-001), is a potent CB1 receptor antagonist intended to rapidly reverse symptoms of cannabis toxicity in both adults (acute cannabinoid intoxication) and children (unintentional cannabis poisoning). The company is advancing an intravenous formulation for pediatric use and completed a Phase 2 oral selonabant trial in the Netherlands involving 134 subjects.
Q2 FY2026 — expected 2026-09-21
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-09-29 | 2025-06-30 | 0001493152-25-016015 | EDGAR | 81K words |
| 2024-09-25 | 2024-06-30 | 0001493152-24-038127 | EDGAR | 79K words |
| 2023-09-22 | 2023-06-30 | 0001493152-23-033452 | EDGAR | 56K words |
| 2022-09-09 | 2022-06-30 | 0001493152-22-025448 | EDGAR | 52K words |
| 2021-09-22 | 2021-06-30 | 0001493152-21-023373 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-12 | 2025-12-31 | 0001493152-26-006446 | EDGAR | 21K words |
| 2025-11-13 | 2025-09-30 | 0001493152-25-022350 | EDGAR | 19K words |
| 2025-05-13 | 2025-03-31 | 0001641172-25-009975 | EDGAR | 20K words |
| 2025-02-14 | 2024-12-31 | 0001493152-25-006893 | EDGAR | 18K words |
| 2024-11-13 | 2024-09-30 | 0001493152-24-045151 | EDGAR | 15K words |
| 2024-05-15 | 2024-03-31 | 0001493152-24-019922 | EDGAR | 43K words |
| 2024-02-13 | 2023-12-31 | 0001493152-24-006103 | EDGAR | 42K words |
| 2023-11-14 | 2023-09-30 | 0001493152-23-041171 | EDGAR | 41K words |
| 2023-05-11 | 2023-03-31 | 0001493152-23-016382 | EDGAR | 38K words |
| 2023-02-10 | 2022-12-31 | 0001493152-23-004203 | EDGAR | 37K words |
| 2022-11-10 | 2022-09-30 | 0001493152-22-031239 | EDGAR | 36K words |
| 2022-05-11 | 2022-03-31 | 0001493152-22-012848 | EDGAR | 14K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-12 | 0001493152-26-006428 | EDGAR | 1K words |
| 2026-02-06 | 0001493152-26-005463 | EDGAR | 1K words |
| 2026-01-29 | 0001493152-26-004154 | EDGAR | 1K words |
| 2026-01-27 | 0001493152-26-003718 | EDGAR | 1K words |
| 2025-12-22 | 0001493152-25-028676 | EDGAR | 1K words |
| 2025-11-13 | 0001493152-25-022310 | EDGAR | 2K words |
| 2025-09-29 | 0001493152-25-016001 | EDGAR | 3K words |
| 2025-09-12 | 0001493152-25-013133 | EDGAR | 1K words |
| 2025-07-23 | 0001493152-25-011342 | EDGAR | 1K words |
| 2025-05-13 | 0001641172-25-009952 | EDGAR | 2K words |
82 total filings indexed. 55 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001815974 |
| Ticker | ANEB |
| Exchange | OTC |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ANEB (~200 tokens, structured JSON with cryptographic provenance)